Prion diseases, or transmissible spongiform encephalopathies, are invariably lethal neurodegenerative illnesses that affect humans and many animal species. They include bovine spongiform encephalopathy of cattle, chronic wasting disease of mule deer and elk, and Creutzfeldt-Jakob disease (CJD) in humans (3) . The causative agent is termed a prion (36) and was proposed to be identical to PrP Sc , a pathological conformer of the cellular protein PrP c encoded by the Prnp gene (31) . PrP C is expressed on the surfaces of almost all cells in the body but at particularly high levels on neurons in the peripheral and central nervous systems. PrP C is essential for the development of prion disease (7) , and Prnp o/o mice, which lack PrP C , are resistant to scrapie (8) .
The bovine spongiform encephalopathy epidemic (42) can be arguably deemed the direct consequence of flawed technology assessment and is caused by prions that were amplified through the bovine food chain (41) . Transmission of bovine prions to humans has then given rise to variant CJD (44) . At the time of this writing, Switzerland is experiencing an alarming increase in the incidence of a form of CJD which is clinically and biochemically indistinguishable from sporadic CJD and whose cause has not yet been conclusively determined (11, 12) . Also, the recent increase in chronic wasting disease in North America (38) underlines the fact that prion diseases of farm and wildlife animals still represent a threat to public health. For all the reasons enumerated above, there is an urgent and growing need for efficient preventive and/or therapeutic measures against prion diseases (2) .
Prions use immune cells to gain access to the brain (14, 20, 35) . On the other hand, several reports indicate that humoral immune responses against the prion protein can antagonize prion infections. This is true even when such responses are directed primarily against PrP C and do not selectively target the disease-associated prion protein, PrP Sc . For example, monoclonal antibodies directed against PrP C have been shown to prevent de novo scrapie infection and to abrogate prion infectivity and PrP Sc from chronically scrapie-infected neuroblastoma cells (10, 33) . Transgenic expression (16) or peripheral administration of anti-PrP antibodies in mice (43) can arrest peripheral scrapie pathogenesis, and PrP-Fc␥ fusion molecules interfere with prion replication (30) .
One major obstacle to devising efficacious regimens of active immunization is host tolerance to endogenous PrP C that inhibits a host-derived anti-PrP antibody immune response. Active immunization attempts have thus far resulted in the induction of meager anti-PrP titers at best (13, 22, 34, 39) . Accordingly, the biological efficacy of these immunization series was limited (34, 39) , emphasizing the need for alternative strategies.
Conversely, administration of antibodies generated in Prnpablated animals ("passive immunization"), while feasible and effective (43) , suffers from the intrinsic problem of poor diffusion from vessels into tissues, particularly into the central nervous tissue. This may explain why administration of monoclonal antibodies has been shown to prevent prion pathogenesis only when applied simultaneously or shortly after peripheral prion infection (43) . In addition, production of the large amounts of monoclonal antibodies necessary for the treatment of human patients is technically challenging and expensive (18, 25, 28) .
Delivery of antibodies by gene therapy may circumvent the limitations described above by providing a steady, localized supply of antibodies which obviates the need for repetitive injections. However, whole antibodies are unwieldy and undergo a complex biogenesis, and their large genes are poorly suitable for efficient genetic transfer with vectors. Worryingly, intracerebral injection of anti-PrP immunoglobulin G (IgG) antibodies was found to provoke neurotoxicity by cross-linking PrP C (40) . One possible solution to the latter problems is offered by the use of phage display-based single-chain miniantibodies (scFvs), which are small and consist of a single fusion polypeptide. ScFvs are often derived from natural or synthetic cDNA libraries, but they can also be engineered from the sequences encoding the variable regions of individual hybridomas. In the latter case, scFvs retain the antigen binding properties of the parent monoclonal antibody (19, 24, 26, 45) . Here we tested a novel strategy of paracrine immunization that employs soluble scFvs with anti-PrP specificity. We find that secretion of antiPrP scFvs by mammalian cells cures chronically prion-infected N2a neuroblastoma cells (ScN2a). These results suggest that open reading frames (ORFs) encoding anti-PrP scFvs may be used in gene therapy against prion diseases.
hanced chemiluminescence (ECL kit; Pierce, Rockford, IL). Alternatively, membranes were incubated with monoclonal anti-c-myc antibody 4A6 (Upstate) and probed with horseradish peroxidase-labeled anti-mouse IgG1 antibody (Zymed).
Dot and slot blotting. Recombinant PrP at a concentration of 200 ng was diluted in 100 l of phosphate-buffered saline (PBS) and dotted or slotted onto a nitrocellulose membrane. The membrane was air dried, blocked with 5% skim milk in TBST (10 mM Tris-HCl, pH 7.8, 10 mM NaCl, and 0.05% Tween 20) , and incubated with a 1:2 dilution of conditioned medium with TBST for 2 h in a final volume of 3 ml. After three washing steps (5 min) with TBST, scFv binding was detected with horseradish peroxidase-conjugated monoclonal anti-His 6 antibody (Invitrogen) and thereafter visualized by enhanced chemiluminescence (ECL kit; Pierce, Rockford, IL).
Cell blot assay. The cell blot assay was performed as described by Bosque and Prusiner (6) . Cells were transferred to nitrocellulose membrane, treated with proteinase K, denatured, immunostained with monoclonal antibody 6H4 followed by a horseradish peroxidase-conjugated goat anti-mouse IgG1 antibody, and visualized by enhanced chemiluminescence (ECL kit; Pierce, Rockford, IL). To assess the extent of transfer of cells to the nitrocellulose membrane, membranes were stained with 0.5 g/ml ethidium bromide for 15 min and photographed in UV light as described previously (10) .
Enrichment and purification of scFvs. Supernatants derived from transiently transfected HEK-293 cells were enriched for scFvs of clone 4.1 or 4.5 by use of centrifugal filter devices with an ability to retain molecules above 10 kDa (Amicon Ultra; Millipore) or purified by His 6 affinity and fast protein liquid chromatography using a nickel-nitrilotriacetic acid (Ni-NTA) kit (QIAGEN) according to the manufacturer's description.
Anti-PrP ELISA. Ninety-six-well plates were coated with 5 g/ml mouse recombinant PrP (PrP REC ) overnight at 4°C. Plates were washed with PBS containing 0.1% (vol/vol) Tween 20 (PBST) and blocked with PBST containing 5% bovine serum albumin for 2 h at room temperature (RT). After washing, plates were incubated with 50 l of serially twofold diluted cell culture supernatant purified for scFvs or, as technical control, monoclonal antibody POM1 to mouse PrP. After 2 h at RT, plates were thoroughly washed and probed with a horseradish peroxidase-conjugated monoclonal anti-c-myc or anti-His antibody (both from Invitrogen; 1:5000 dilution) for 1 h at RT, except for wells incubated with POM1, which were probed with horseradish peroxidase-conjugated rabbit anti-mouse IgG (Zymed; 1:000 dilution). Plates were developed with tetramethyl benzidine, and optical density was measured at 450 nm. For competition experiments, PrP REC -coated plates were pretreated with serial 10-fold dilutions of monoclonal antibody POM1 or POM2 (from 2 g to 2 ng/well) for 2 h at RT before addition of purified scFvs of clone 4.1 or 4.5.
Antibodies. Monoclonal mouse anti-PrP antibodies POM1 and POM2 (both 
RESULTS
Expression and secretion of anti-PrP scFv in mammalian cells. We report the construction of two clones of phages (termed sc4.1 and sc4.5) displaying the Fv portions of the heavy and light chains of monoclonal antibody 6H4 (23) as a single-chain fusion protein (scFv). Antibody 6H4 displays a high affinity for PrP C and was previously shown to interfere with the buildup of PrP Sc and of prions in vitro (10) and in transgenic mice (16) . The clones were selected by a panning assay against recombinant full-length PrP (PrP REC ) and sequenced. The ORFs of clones sc4.1 and sc4.5 were inserted into the plasmid vector pSecTag2/Hygro (Invitrogen) in order to allow for eukaryotic expression. pSecTag2/Hygro contains the CMV promoter, an Ig leader sequence specifying secretion of heterologous proteins, a c-myc tag at the C terminus, and a hexahistidine tag allowing for detection and purification through immobilized metal affinity chromatography with nickelchelating resin (Fig. 1a) . As a positive control for expression . 1a) .
To assess transcription of pSecTag2/Hygro-sc4.1 and pSecTag2/Hygro-sc4.5, the human rhabdomyosarcoma cell line RD-4 (9) was transiently transfected, total RNA was isolated 48 h after transfection, and Northern blotting was performed using a probe spanning the full scFv ORF (Fig. 1b) . A plasmid expressing green fluorescent protein (GFP) under the control of the CMV promoter (pEGFP-C1) was cotransfected to monitor the efficiency of transfection.
Next, we assessed translation and secretion of pSecTag2/ Hygro-sc4.1 and pSecTag2/Hygro-sc4. 4 ]. Constructs were placed under the control of the CMV enhancer and promoter (627 bp) and fused to an amino-terminal Ig leader sequence and a carboxy-terminal c-myc/His 6 tag. The restriction sites utilized for the cloning and the signal peptide cleavage site are indicated. For a control, the ORF of PSA (690 bp) was fused to the amino-terminal Ig leader sequence and a carboxy-terminal c-myc/His 6 tag. In order to be able to monitor the efficiency of transfection, the ORF of GFP (731 bp medium was loaded on a 12% sodium dodecyl sulfate-polyacrylamide gel. Correct protein expression of sc4.1 and sc4.5 was indicated by the presence of a protein with a molecular mass of ϳ36 kDa visualized by antibodies to the fused c-myc tag (Fig. 1c) . Further, Ni 2ϩ chelation chromatography resulted in an enrichment of anti-PrP scFvs (Fig. 1d) . These findings indicate that anti-PrP scFvs were translated and correctly processed by the cellular export apparatus, resulting in their secretion into the medium of cultured cells.
Secreted anti-PrP scFvs recognize PrP REC . In order to test whether secreted anti-PrP scFvs retain their anti-PrP binding activity, supernatants from transiently transfected RD-4 cells were analyzed by dot blotting and by slot blotting. Binding of scFvs was visualized with anti-His antibodies. We found that conditioned medium derived from sc4.1, but not that derived from sc4.5 or from any of the negative controls, recognized PrP REC (Fig. 2a) . If the binding of clone sc4.1 to PrP REC represents a specific scFv-antigen interaction, it should compete with the binding of its parental monoclonal antibody 6H4, from which both sc4.1 and sc4.5 were derived. To investigate this question, nitrocellulose membranes were blotted with PrP REC and preincubated with monoclonal antibody 6H4 (100 ng/ml), which recognizes residues 144 to 152 of mouse PrP C (23) . After such pretreatment of the membrane, sc4.1 no longer reacted to PrP REC . In contrast, preincubation with an IgG isotype control antibody (100 ng/ml; Zymed) did not prevent binding (Fig. 2b) .
To investigate the specificity and sensitivity of binding to PrP REC , Ni-NTA-purified scFvs of transiently transfected HEK-293 cells were analyzed by ELISA on plates coated with PrP REC and visualized with anti-His antibodies. We detected strong specific binding of sc4.1, whereas sc4.5 showed no reactivity ( Fig. 2c and d) , even when taking into account the fact that the concentration of sc4.5 was ϳ4-fold lower than that of sc4.1 (Fig. 2e) .
Competition assays further demonstrated that sc4.1 binds a PrP epitope overlapping that of monoclonal antibody 6H4 (Fig. 2f) . Remarkably, sc4.1 was displaced from PrP REC by 6H4 only when the latter holoantibody was added at concentrations of 2 g/ml (corresponding to 200 ng/well) or higher (Fig. 2f) . Such concentrations of 6H4 were previously shown to be sufficient to clear prion infection from cultured chronically prion-infected N2a cells (10) .
To explore their differences in binding to PrP REC , the primary amino acid sequences of sc4.1 and sc4.5 were analyzed and found to differ in three amino acids at positions 58, 61, and 293 (Fig. 3) . Dissimilarities at residues 58 and 61 were detected within framework region 1 of the light chain, whereas the mutation at amino acid 293 was positioned in framework region 4 of the heavy chain right after the complementaritydetermining region 3. The complementarity-determining regions form loops which contribute to the critical interaction between the antibody and ligand. Differences in the framework regions, particularly in close vicinity to complementarity-determining region 3, which is the main determinant for antigen binding (4), may destabilize folding (32, 47) and therefore may explain the lack of PrP C affinity in sc4.5. Therefore, in all subsequent experiments, clone sc4.5 was operationally regarded as of irrelevant specificity and served as a negative control.
Secreted anti-PrP scFvs abolish PrP
Sc in cocultured prioninfected N2a/Bos2 cells. In order to test for the prionostatic effects of anti-PrP scFvs, we cocultured RD-4 cells stably transfected with pSecTag2/Hygro4.1 in the presence of chronically scrapie-infected N2a/Bos2 neuroblastoma cells (6) . Stably transfected RD-4 cells producing anti-PrP scFvs (Fig. 4a) were separated by transwell membranes from chronically prion-infected N2a/Bos2 cells (Fig. 4b) . Although chronically prioninfected N2a/Bos2 cells shared their medium with anti-PrPscFv-producing cells, no direct cell-cell contact between stably transfected RD-4 and N2a/Bos2 cells was possible. This experimental design was chosen in order to simulate a paracrine situation, in which cells expressing scFv may coexist in the same organ with cells that may be infected with prions but do not express the antibody.
After 3 weeks of coculturing, including subpassaging of N2a/ Bos2 cells, and change of the transwell membranes with stably transfected RD-4 cells, the presence of PrP Sc in N2a/Bos2 cells was analyzed by cell blotting (6, 10) . We found a drastic reduction of PrP Sc in prion-infected N2a/Bos2 cells cocultured with RD-4 cells producing anti-PrP scFvs (sc4.1), whereas no reduction in PrP Sc load was observed in N2a/Bos2 cells cocultured with any of the controls (Fig. 4c) . Interestingly, the decrease in PrP Sc was dependent on the amount of anti-PrP scFv expression, since clones of RD-4 cells stably transfected with the same anti-PrP scFvs construct (clone sc4.1) with low expression were less efficient in clearing PrP Sc than clones with high expression (Fig. 4a to c) . N2a/Bos2 cells treated with anti-PrP scFvs (sc4.1) maintained reduced levels of PrP Sc for at least three further passages (corresponding to 12 days) in the absence of additional anti-PrP scFv treatment (Fig. 5) .
DISCUSSION
The prospect of immunotherapy against prion diseases has received considerable attention in recent years. Encouraging results with cell culture systems and with mouse models have raised hopes that antibodies may prove useful at retarding or even at blocking prion replication. However, classical vaccination in wild-type animals appears to be extremely difficult because of host tolerance to endogenous PrP C (15, 34) . We therefore reasoned that delivery of antibody-like molecules by gene transfer may be worth investigating, as it might bypass the tolerance problem described above. We have therefore set out to employ protein engineering to determine whether it is possible to express and secrete monovalent single-chain miniantibodies (scFvs, which are most frequently produced in prokaryotic systems) specific to PrP in mammalian cells.
Genetic engineering of antibodies has been utilized in a variety of ways to address the limitations encountered with monoclonal antibodies (17) . In particular, generation of scFv moieties with specificities identical to those of their parental monoclonal antibodies has allowed reduction of neutralizing and potentially adverse immune responses against holoantibodies and improvement of biodistribution (37) . In this respect, the results presented here suggest that secreted forms of anti-PrP scFv may represent a useful approach to the delivery of antiprion immunotherapeutic agents.
Administration of anti-PrP scFv presents several distinct advantages over the use of monoclonal holoantibodies. In par- ticular, the delivery of scFvs by genetic transduction in vivo, e.g., by means of viral vectors, may allow for sustained production of scFvs at predefined sites for prolonged periods of time. This is difficult to obtain by direct systemic administration of monoclonal antibodies, which are very large molecules and therefore may present limited bioavailability, and by injection of recombinant scFvs, which have extremely short half-lives in blood.
On the other hand, scFv fragments lack all effector domains of holoantibodies, including Fc␥ and complement binding domains. Since components of the complement system are involved in pathogenesis of scrapie (21, 27) , we deemed it particularly important to assess whether the antiprion biological activity of scFv fragments is similar to that of full-fledged holoantibodies. The coculture studies presented here indicate that this may be the case: effector functions encoded by the monoclonal antibodies was innocuous, suggesting that antibody-induced cross-linking of PrP C may be toxic (40) . However, if toxicity is inherent to the bivalent character of monoclonal IgG holoantibodies, as the results mentioned above appear to suggest, one would expect that anti-PrP scFvs, which are monovalent and therefore cannot cross-link PrP C , should be safer than bivalent full-fledged antibodies.
Curing scrapie-infected neuroblastoma cells is likely to be easier than eradicating prions from infected organisms. The bewildering variety of chemicals that appear to suppress prion replication in N2a cells bears witness to the suspicion that activation of a variety of pathways may impair the ability of N2a cells to support prion replication (1) . For this reason, it will be important to confirm the efficacy of any proposed scFvbased immunotherapy in animal models. The comparatively small size of the cDNA that encodes for the scFv described here (957 base pairs) makes it easy to efficiently package it into a variety of viral vectors. Further studies will need to address the feasibility and scalability of this approach. For basic studies of prion replication, transduction of eukaryotic cells with antiPrP scFv fragments may represent a useful tool to suppress prion replication in localized tissue compartments or in specific cell types without interfering with Prnp transcription. With respect to translational research, mammalian cells expressing anti-PrP scFvs may present a therapeutic tool to interfere with prion replication while avoiding problems encountered with classical active or passive PrP immunization.
